This medication is applied across domains where additional symptomatic support is needed in three key therapeutic areas.

The drug is commonly used to help with managing the symptoms of three primary conditions: Erectile Dysfunction (ED), the urinary symptoms associated with Benign Prostatic Hyperplasia (BPH), and supportive management for a type of high blood pressure in the lungs (Pulmonary Arterial Hypertension or PAH).

In the context of ED, it helps address symptoms that create noticeable physiological strain, assisting with maintaining symptomatic support relevant to intimacy. For BPH, it contributes to easing the overall symptom burden related to urinary urgency and weak flow. In the specialized setting of PAH, it supports the management of physical endurance challenges and general comfort.

Quick Fact: Addressing Symptoms of Daily Urinary Discomfort

The medication is utilized when short-term symptomatic assistance is needed across these domains, supporting patients during difficult episodes by easing distress and assisting with maintaining day-to-day comfort.

Regulatory References

1. NIH MedlinePlus overview of Tadalafil

Who Can and Cannot Use Cialis? (Tadalafil)

Official regulatory documents define strict population eligibility for Tadalafil, restricting use primarily to adult males (18 years and older) for its approved indications. Use is absolutely contraindicated in several specific patient groups:

Eligibility Scope	Detail (Strictly Regulatory)
Populations for whom use is contraindicated:	Patients using any form of organic nitrate or the guanylate cyclase stimulator Riociguat. Patients with a history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). Patients with recent severe cardiovascular events, including myocardial infarction (within 90 days) or stroke (within 6 months).
Populations for whom use is not recommended:	Patients with severe hepatic impairment (Child-Pugh Class C). Patients with severe renal impairment (Creatinine Clearance <30 mL/min) for once-daily use. Individuals under 18 years of age (pediatric population).
Age and Gender Eligibility:	The medicine is not indicated for use in women for the treatment of ED/BPH. Safety and efficacy have not been established in the pediatric population.
Conditional Use (Caution):	Caution is required in patients with conditions predisposing them to priapism (e.g., sickle cell anemia) or with anatomical deformation of the penis (e.g., Peyronie’s disease).

The official interaction profile for Tadalafil (Cialis) is defined by its effects on blood pressure and its specific metabolic pathway, leading to required restrictions documented in regulatory labeling.

Classification	Description
Contraindicated Combinations	Co-administration with any form of organic nitrate (e.g., nitroglycerin) is strictly prohibited due to the risk of severe, life-threatening hypotension. Co-administration with Guanylate Cyclase (GC) Stimulators (e.g., Riociguat) is also officially contraindicated.
Pharmacodynamic Interactions	The drug can potentiate the blood pressure-lowering effects of alpha-blockers (e.g., Doxazosin, Terazosin) and general antihypertensive medicinal products, potentially causing symptomatic hypotension.
Pharmacokinetic Interactions	Tadalafil is primarily cleared by the CYP3A4 enzyme. Potent CYP3A4 inhibitors (e.g., Ritonavir, Ketoconazole) officially increase Tadalafil exposure (plasma concentrations), requiring regulatory dose adjustment. CYP3A4 inducers (e.g., Rifampin) decrease exposure, which is anticipated to reduce effectiveness.
Timing Restriction	In a life-threatening emergency requiring nitrate administration, regulatory documents state that at least 48 hours must have passed since the last Tadalafil dose before nitrates can be administered under medical supervision.
Substance Interaction	Co-consumption of substantial amounts of alcohol (ge 5 units) may lead to an increased risk of orthostatic symptoms and lower blood pressure due to combined vasodilatory effects.
Population Consideration	Tadalafil exposure is documented as increased in patients with hepatic impairment and severe renal insufficiency, leading to mandatory dose limitations for these specific populations.

The regulatory documentation strictly classifies these combinations based on the risk of severe hypotension or critical modifications to Tadalafil's concentration in the body. This structure dictates specific prohibitions, cautions regarding concomitant use, and restrictions related to timing and patient health status, as detailed by authoritative health agencies.

How Cialis Works: Mechanism of Action

Selective Enzyme Inhibition

This drug acts as a selective inhibitor of the enzyme Phosphodiesterase Type 5 (PDE5), which is primarily expressed in the smooth muscle cells of vascular tissue. By binding to PDE5, the drug prevents the enzyme from hydrolyzing the signaling molecule cyclic Guanosine Monophosphate (cGMP), resulting in the accumulation of cGMP within the cells.

Pathway Enhancement and Physiological Consequence

The increased concentration of cGMP enhances the effect of the Nitric Oxide (NO) signaling pathway, initiating an intracellular cascade that reduces free calcium levels. This molecular event mediates the relaxation of the arterial smooth muscle cells, leading to vasodilation (vessel widening) in the targeted tissues. This process of targeted modulation of vascular tone facilitates increased local blood flow and tissue engorgement. The mechanism operates by facilitating the effect of a pre-existing signal, meaning the action is reliant on the body's natural signaling process for its commencement.

Official Administration Guidelines

Tadalafil is provided as oral film-coated tablets in strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. The administration protocol is determined by the prescribed regimen, which is divided into as-needed use and continuous once-daily use, and may be taken with or without food.

---

Labeled Dosing Regimens

Regimen	Starting Dose (Typical)	Maximum Single/Daily Dose	Frequency	Timing Rule
As-Needed	10 mg	20 mg	Not more than once per day	Prior to anticipated activity, up to 36 hours before.
Once-Daily (Continuous)	2.5 mg	5 mg	Once daily	Taken at approximately the same time every day.
BPH/ED	—	5 mg	Once daily	Taken at approximately the same time every day.
PAH (Specific Formulation)	—	40 mg	Once daily	Do not divide the dose.

---

Population-Specific Constraints

The official label mandates specific dose limitations for certain patient populations, as adjustments are not required for older adults based on age alone. For individuals with severe renal impairment (CrCl <30 mL/min or on hemodialysis), the maximum dose for as-needed use is limited to 5 mg not more than once every 72 hours, and once-daily dosing is not recommended. For patients with mild to moderate hepatic impairment, the dose for as-needed use should not exceed 10 mg once per day. In the event a dose is missed during continuous daily use, the next dose should be taken at the usual scheduled time; patients must not take a double dose to compensate.

Research Evidence / Overview of Studies for Cialis

Evidence for Use in Erectile Dysfunction (ED)

Research exploring tadalafil for Erectile Dysfunction (ED) has primarily utilized randomized, double-blind, placebo-controlled trials (RCTs). These studies are used in research to compare the drug against an inactive substance (placebo) without the participants or doctors knowing who received which. Research examined adult men with ED that resulted from various factors, including those with common associated health issues like hypertension and diabetes.

Studies were conducted over short time intervals, typically around 12 weeks, to examine how symptom measurements evolved. The primary patient-reported outcomes describing perceived discomfort and functional changes were measured using specific questionnaires, such as the International Index of Erectile Function (IIEF).

Research so far indicates that compared to placebo, studies reported patterns observed in the populations related to higher scores on these key functional questionnaires. However, the initial studies focused mainly on short-term symptom changes. Research regarding long-term changes, particularly the durability of the reported findings over many years, relies more on extended follow-up studies and ongoing observational data. Subgroup findings are uncertain for highly specific patient groups.

---

Evidence for Use in Benign Prostatic Hyperplasia (BPH) Symptoms

Research exploring tadalafil's effect on the lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) utilized multiple randomized, placebo-controlled trials. The main focus was on outcomes related to physical discomfort and systemic imbalance, measured by the International Prostate Symptom Score (IPSS).

While studies reported patterns related to change in the IPSS scores, which contributes to understanding short-term symptom patterns, the data show patterns related to other key measurements being less consistent. For instance, studies that examined the maximum urinary flow rate reported mixed results across the evidence base. This suggests that while research provides context on symptom patterns, findings related to objective physical changes (like flow rate) may vary.

---

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Research was derived from pivotal randomized, placebo-controlled trials conducted under controlled circumstances, typically observing responses over a defined time interval of approximately 16 weeks. Studies focused on outcomes reflecting daily functioning or activity level, with the main measurement being the 6-minute walk distance (6MWD), which tracks functional capacity.

Because PAH is a specialized condition, the evidence is derived from studies where sample sizes were modest compared to common conditions. While research explored short-term symptom changes, long-term effects are not fully established and require continuous monitoring and assessment through specialized registries and extended follow-up, which is ongoing.

---

Evidence Gaps and Areas of Uncertainty

A consistent pattern across the evidence base is that follow-up durations were limited in the initial, high-certainty randomized controlled trials. This means that a key evidence gap is the lack of detailed, high-quality data on the very long-term effects of treatment beyond 1–2 years. Another area where comparative evidence is lacking is in direct, head-to-head trials against all other existing treatments for the same conditions. Evidence quality varies across studies when trying to draw broad conclusions about superiority or distinct advantage.

Common questions about Cialis (FAQ)

Q: What are the two main medical conditions Cialis is approved to treat?

Official product information confirms that Cialis is indicated for the treatment of erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH). These are the two primary uses approved for this specific brand name product.

Q: What is the difference between Cialis and the drug Adcirca, both containing tadalafil?

While both Cialis and Adcirca contain the same active ingredient, tadalafil, regulatory documents define them for different medical conditions. Cialis is approved for ED and BPH. Adcirca is a distinct formulation of tadalafil approved for treating pulmonary arterial hypertension (PAH).

Q: Can consuming a meal affect the speed at which Cialis takes effect?

The official administration guidelines note that Cialis can be taken with or without food. However, studies show that while a large, high-fat meal does not affect the total amount of the drug absorbed, it may slightly delay the time it takes to reach its maximum concentration in the body.

Q: What is priapism, and what are the official guidelines regarding a prolonged erection while taking Cialis?

Priapism is defined in official warnings as a rare, persistent, and painful erection that lasts longer than four hours. Regulatory documents caution that if this occurs, immediate medical attention is required, as untreated priapism can potentially lead to irreversible tissue damage.

Q: Does Cialis cause changes in blood pressure, and is it usually an increase or decrease?

According to the drug's mechanism of action, it works by relaxing the walls of blood vessels. This effect often results in a reduction (decrease) in blood pressure. This physiological effect is the reason regulatory warnings exist regarding its co-administration with other blood pressure-lowering medications.

Q: Does Cialis work if a person is not sexually aroused?

The drug's mechanism of action is described as facilitating the body's natural signaling process. Therefore, according to official information, sexual stimulation is necessary for the medication's action to begin and produce an erection.

Q: Is Cialis considered a cure for erectile dysfunction (ED)?

Cialis is approved for the treatment of the symptoms of erectile dysfunction. Regulatory information consistently describes the medication as a treatment method and does not state that it is a cure for the underlying condition.

Q: Does taking Cialis affect a person's sexual desire or libido?

The official mechanism of action focuses exclusively on modulating blood flow within specific tissues. Regulatory documents do not list changes in libido or sexual desire as a known adverse reaction.

Q: How quickly does Cialis typically start to work after a single dose?

For on-demand use, studies indicate that the medication may begin to work in as little as 30 minutes after ingestion. Individual time to onset can vary, but this range reflects the findings from clinical research.

Q: Is the maximum effect felt immediately after onset, or does it take longer?

Official studies show that the maximum concentration of the drug in the blood, known as Cmax, is typically reached within two hours of administration. This time point reflects the peak level of the drug substance in the bloodstream.

Q: Why might it take several days of consistent use to feel the full effect of the daily dose?

For the continuous once-daily dosing regimen, it takes time for the drug to build up in the body. Official pharmacological data indicates it takes approximately five days to reach a steady-state concentration, which is required for the full therapeutic effect.

Q: Is it common for the effective duration to be less than the full 36 hours?

The maximum duration of action is reported as up to 36 hours. Official information acknowledges that the duration and effectiveness can vary based on individual physiological factors, such as the person's drug clearance rate and required level of response.

Q: Does the time it takes to work differ between the daily and the on-demand doses?

Once the daily dosing regimen has established a steady-state concentration, the drug is continually present in the body. This provides continuous availability rather than relying on a single rapid onset event, as is the case with on-demand use.

Q: Is there a difference in side effect risks between the brand name and the generic form?

Regulatory standards require generic forms of tadalafil to meet the same strict bioequivalence standards as the brand-name product. This means that both forms are expected to have the same intended effect and the same overall safety profile.

Q: Does the risk of experiencing side effects increase with a higher dose?

Clinical research data indicates that the risk and frequency of certain commonly reported adverse reactions, such as headache and indigestion (dyspepsia), generally increase with the amount of the dose taken.

Q: Is it safe to consume grapefruit or grapefruit juice while taking Cialis?

Grapefruit is recognized as an inhibitor of the CYP3A4 enzyme, which is responsible for metabolizing tadalafil. Official warnings about CYP3A4 inhibitors state that they can significantly increase the concentration of the drug in the body, which is a factor addressed in the official interaction profile.

Q: Are there any herbal supplements or over-the-counter drugs known to interact with Cialis?

Official interaction warnings focus on strong inhibitors and inducers of the CYP3A4 enzyme. Regulatory documents advise that certain prescription, herbal, and non-prescription items can affect this enzyme, potentially modifying the drug's concentration.

Q: Does Cialis contain lactose or other ingredients that can cause allergic reactions in sensitive individuals?

Cialis is an oral tablet that contains lactose monohydrate as an excipient (inactive ingredient). The full list of inactive ingredients that make up the tablet is published in the official prescribing information for the drug.

Official Storage and Disposal Requirements for Cialis (Tadalafil)

The storage and disposal of Cialis are governed by strict regulatory guidelines to maintain product stability and safety. This information is based on official government labeling from health authorities.

Storage Conditions:

• Store Cialis at room temperature, typically below 30 C.
• It must be kept in its original package to protect from moisture.
• Do not freeze the medication, and keep it away from excessive heat.
• Always keep the tablets out of the sight and reach of children.

Disposal Rules:

• Do not use Cialis after the expiration date printed on the packaging.
• Unused or expired medication must be disposed of in accordance with local requirements for pharmaceutical waste.
• Disposal methods often include participating in drug take-back programs or, if unavailable, mixing the tablets with an undesirable substance (like dirt or cat litter) before placing them in a sealed bag for household trash.